OncRef

Clinical Trial: NCT05891171

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:Arcus Biosciences, Inc.
Information Provided By:Arcus Biosciences, Inc.
Last Update Posted:2026-09-29

Study Overview

Brief Summary

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Official Title

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Conditions

Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)

Intervention / Treatment

  • Drug: AB598
  • Drug: Zimberelimab
  • Drug: Fluorouracil
  • Drug: Leucovorin
  • Drug: Oxaliplatin

Other Study ID Numbers

  • ARC-25

Start Date (Actual)

2023-10-13

Primary Completion Date (Estimated)

2027-09

Study Completion Date (Estimated)

2027-09

Enrollment (Actual)

40

Study Type

Interventional

Phase

Phase 1